Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumacaftor-ivacaftor Effect on Hyperglycemia in Cystic Fibrosis
NCT02858843Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of lumacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Massachusetts General Hospital. Primary endpoints: Change in glycated hemoglobin at 1 year and Change in units of insulin used at 1 year. Started Aug 2016; status: terminated.
02
Drugs
lumacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02858843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858843.